SubsidieMeestersFlow Controlled Prosthetic Heart Valves
StreamlineValve aims to develop a flow-controlled prosthetic heart valve that enhances durability and safety while reducing the need for anticoagulation therapy through optimized blood flow.
Projectdetails
Introduction
Prosthetic Heart Valves (HV), both biological (BHV) and mechanical (MHV), have improved the survival rate and the quality of life of valvular heart-disease patients over the last six decades. While BHVs, taken from animal tissue, show improved hemodynamics, their durability is limited.
Mechanical Heart Valves
On the other hand, MHVs can last a patient's entire lifetime but require lifetime anticoagulation medication to reduce thrombotic complications. Future Polymeric HVs (PHV) hold the potential for enhanced durability compared to BHVs, while potentially avoiding the necessity for anticoagulation therapy that MHVs demand. However, the problem of flow-related thrombosis in PHVs remains a critical challenge.
Flow-Related Thrombosis
Generally, flow-related thrombosis complications can be avoided by altering the flow field around the PHV. This can be achieved by:
- Reducing vortices and circulatory hemodynamic structures.
- Decreasing shear stresses which can lead to platelet activation.
Flow Control Strategy
Inspired by passive flow control in nature and in the aerodynamics industry, where manipulation of fluid flow via a small configuration change provides large engineering benefits in swimming or flying, we aim to use a flow control strategy to optimize blood flow through PHVs.
StreamlineValve
More specifically, in StreamlineValve, we present a new, patented PHV that is designed to alter the flow field around the valve in a manner that reduces the primary factors contributing to coagulation on PHVs. We have already successfully demonstrated this concept in vitro in a modified MHV.
Proof of Concept
In this PoC, we propose to extend this to the future of prosthetic valves via a flow-controlled PHV that can be implanted via a simple transcatheter procedure, avoiding undesired surgical procedures.
Conclusion
Altogether, StreamlineValve represents a paradigm shift in the realm of prosthetic HVs, offering the potential to enhance valve longevity, quality of life, and patient safety.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-3-2024 |
| Einddatum | 31-8-2025 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- TECHNION - ISRAEL INSTITUTE OF TECHNOLOGYpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
biomimetic engineered chordae tendineae for valve repair and regenerationThis project aims to develop and validate BioChord, a bioengineered regenerative chordae tendineae for mitral valve repair, enhancing durability and promoting tissue restoration. | ERC Proof of... | € 150.000 | 2023 | Details |
Prognostic assessment of valvular aortic disease treatment coupling Immunological and biomechanical profilesProtego aims to develop a predictive methodology combining immunological and biomechanical profiles to optimize treatment timing and outcomes for patients with aortic valve diseases, reducing complications. | ERC Starting... | € 1.498.295 | 2024 | Details |
Advanced human models of the heart to understand cardiovascular diseaseHeart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine. | ERC Advanced... | € 2.500.000 | 2023 | Details |
Fluid-Structure Interaction and Machine Leaning for Controlling Unruptured Intracranial AneurysmsThis project aims to enhance intracranial aneurysm treatment by developing predictive models and novel stent designs using advanced computational methods and deep reinforcement learning. | ERC Consolid... | € 1.891.333 | 2023 | Details |
Clonal hematopoesis of indeterminate potential and degenerative aortic valve stenosisThis project aims to investigate the impact of DNMT3A mutations on aortic valve stenosis progression and cardiac fibrosis, seeking biomarkers and therapeutic targets for high-risk patients. | ERC Advanced... | € 2.225.906 | 2022 | Details |
biomimetic engineered chordae tendineae for valve repair and regeneration
This project aims to develop and validate BioChord, a bioengineered regenerative chordae tendineae for mitral valve repair, enhancing durability and promoting tissue restoration.
Prognostic assessment of valvular aortic disease treatment coupling Immunological and biomechanical profiles
Protego aims to develop a predictive methodology combining immunological and biomechanical profiles to optimize treatment timing and outcomes for patients with aortic valve diseases, reducing complications.
Advanced human models of the heart to understand cardiovascular disease
Heart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine.
Fluid-Structure Interaction and Machine Leaning for Controlling Unruptured Intracranial Aneurysms
This project aims to enhance intracranial aneurysm treatment by developing predictive models and novel stent designs using advanced computational methods and deep reinforcement learning.
Clonal hematopoesis of indeterminate potential and degenerative aortic valve stenosis
This project aims to investigate the impact of DNMT3A mutations on aortic valve stenosis progression and cardiac fibrosis, seeking biomarkers and therapeutic targets for high-risk patients.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A prosthetic heart valve for adults and children, made from the patient’s own tissue, a replacement heart valve that lasts a lifetimeGrOwnValve aims to revolutionize heart valve technology by creating lifelong autologous valves from patients' own tissue using 3D printing, reducing rejection and the need for multiple surgeries. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Transcatheter Ventricular Repair Device for treatment of Heart Failure PatientsCardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Minimally invasive suturing for vascular bore closure and heart defect repairNovelrad's NVCD closure device aims to minimize complications in large-bore vascular closures during cardiac surgeries through innovative micro-suturing technology, facilitating safer and faster procedures. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Saving patients from severe heart failureThe ICOMS FlowMaker® is a novel intracardiac assist device designed to improve the quality of life for severe heart failure patients, aiming for EU market entry by 2026 through clinical trials. | EIC Accelerator | € 2.500.000 | 2022 | Details |
LFHP VentielDe aanvrager ontwikkelt een innovatieve lage flow-hoge druk proportioneel regelventiel om de efficiëntie van chemische processen te verbeteren, afhankelijk van een haalbaarheidsstudie. | Mkb-innovati... | € 20.000 | 2020 | Details |
A prosthetic heart valve for adults and children, made from the patient’s own tissue, a replacement heart valve that lasts a lifetime
GrOwnValve aims to revolutionize heart valve technology by creating lifelong autologous valves from patients' own tissue using 3D printing, reducing rejection and the need for multiple surgeries.
Transcatheter Ventricular Repair Device for treatment of Heart Failure Patients
Cardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing.
Minimally invasive suturing for vascular bore closure and heart defect repair
Novelrad's NVCD closure device aims to minimize complications in large-bore vascular closures during cardiac surgeries through innovative micro-suturing technology, facilitating safer and faster procedures.
Saving patients from severe heart failure
The ICOMS FlowMaker® is a novel intracardiac assist device designed to improve the quality of life for severe heart failure patients, aiming for EU market entry by 2026 through clinical trials.
LFHP Ventiel
De aanvrager ontwikkelt een innovatieve lage flow-hoge druk proportioneel regelventiel om de efficiëntie van chemische processen te verbeteren, afhankelijk van een haalbaarheidsstudie.